Pneumococcal vaccine - ImmunoBiology

Drug Profile

Pneumococcal vaccine - ImmunoBiology

Alternative Names: PnuBioVax™

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator ImmunoBiology
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Pneumococcal infections

Most Recent Events

  • 01 Sep 2016 ImmunoBiology completes a phase-I clinical trial in Pneumococcal infections (In volunteers) in United Kingdom (IM) (NCT02572635)
  • 30 Jun 2016 Efficacy, Adverse events and Immunogenicity data from a phase I trial in Healthy volunteers released by ImmunoBiology
  • 10 Dec 2015 Pneumococcal vaccine - ImmunoBiology is available for licensing as of 10 Dec 2015. www.immbio.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top